FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091240978> ?p ?o ?g. }

• W2091240978 endingPage "734" @default.
• W2091240978 startingPage "729" @default.
• W2091240978 abstract "Purpose The positive role of radiotherapy for patients with lymph node (LN) metastasis from hepatocellular carcinoma has recently been reported. The outcome and prognostic factors for these patients were analyzed. Methods and Materials Between May 2004 and October 2007, 38 patients with LN metastases from hepatocellular carcinoma underwent radiotherapy. The median age was 59 years (range, 42–81). The radiation dose was 35–56 Gy with a fraction size of 1.8–3 Gy, for a biologically effective dose of 43.75–67.2 Gy10 (median, 59.0). The median follow-up period was 8 months. Results The median survival time was 10 months. On univariate analysis, Child-Pugh class B (p = .0006), distant metastasis (p = .0095), symptoms related to metastatic LNs (p <.0001), and a biologically effective dose <60 Gy10 (p = .0042) were significant prognostic factors predicting for poor overall survival. On multivariate analysis after adjustment using the Benjamini and Hochberg (false discovery rate) method, Child-Pugh class B (p = .04095) and the presence of symptoms (p = .04095) were associated with inferior overall survival. When patients were divided into three groups according to these two risk factors, the median survival for patients with no, either, or both risk factors was 20, 7, and 4 months, respectively (p <.0001). Conclusion Patients with intact liver function and without related symptoms had the best prognosis when undergoing radiotherapy for LN metastasis from hepatocellular carcinoma. The positive role of radiotherapy for patients with lymph node (LN) metastasis from hepatocellular carcinoma has recently been reported. The outcome and prognostic factors for these patients were analyzed. Between May 2004 and October 2007, 38 patients with LN metastases from hepatocellular carcinoma underwent radiotherapy. The median age was 59 years (range, 42–81). The radiation dose was 35–56 Gy with a fraction size of 1.8–3 Gy, for a biologically effective dose of 43.75–67.2 Gy10 (median, 59.0). The median follow-up period was 8 months. The median survival time was 10 months. On univariate analysis, Child-Pugh class B (p = .0006), distant metastasis (p = .0095), symptoms related to metastatic LNs (p <.0001), and a biologically effective dose <60 Gy10 (p = .0042) were significant prognostic factors predicting for poor overall survival. On multivariate analysis after adjustment using the Benjamini and Hochberg (false discovery rate) method, Child-Pugh class B (p = .04095) and the presence of symptoms (p = .04095) were associated with inferior overall survival. When patients were divided into three groups according to these two risk factors, the median survival for patients with no, either, or both risk factors was 20, 7, and 4 months, respectively (p <.0001). Patients with intact liver function and without related symptoms had the best prognosis when undergoing radiotherapy for LN metastasis from hepatocellular carcinoma." @default.
• W2091240978 created "2016-06-24" @default.
• W2091240978 creator A5011410839 @default.
• W2091240978 creator A5013664294 @default.
• W2091240978 creator A5015422568 @default.
• W2091240978 creator A5019669804 @default.
• W2091240978 creator A5035961207 @default.
• W2091240978 creator A5089681505 @default.
• W2091240978 creator A5089784777 @default.
• W2091240978 date "2010-11-01" @default.
• W2091240978 modified "2023-10-16" @default.
• W2091240978 title "Absence of Symptom and Intact Liver Function Are Positive Prognosticators for Patients Undergoing Radiotherapy for Lymph Node Metastasis From Hepatocellular Carcinoma" @default.
• W2091240978 cites W146043871 @default.
• W2091240978 cites W1976091842 @default.
• W2091240978 cites W1982068113 @default.
• W2091240978 cites W1991267517 @default.
• W2091240978 cites W1992173077 @default.
• W2091240978 cites W1993128964 @default.
• W2091240978 cites W1994193851 @default.
• W2091240978 cites W2018357401 @default.
• W2091240978 cites W2020943077 @default.
• W2091240978 cites W2043945205 @default.
• W2091240978 cites W2069486732 @default.
• W2091240978 cites W2069672858 @default.
• W2091240978 cites W2080551495 @default.
• W2091240978 cites W2090028057 @default.
• W2091240978 cites W2095455032 @default.
• W2091240978 cites W2121707384 @default.
• W2091240978 cites W2128979905 @default.
• W2091240978 cites W2139394490 @default.
• W2091240978 cites W2146128193 @default.
• W2091240978 cites W2147172608 @default.
• W2091240978 cites W2154204813 @default.
• W2091240978 cites W2591170673 @default.
• W2091240978 cites W4293241248 @default.
• W2091240978 doi "https://doi.org/10.1016/j.ijrobp.2009.08.047" @default.
• W2091240978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20171806" @default.
• W2091240978 hasPublicationYear "2010" @default.
• W2091240978 type Work @default.
• W2091240978 sameAs 2091240978 @default.
• W2091240978 citedByCount "18" @default.
• W2091240978 countsByYear W20912409782012 @default.
• W2091240978 countsByYear W20912409782013 @default.
• W2091240978 countsByYear W20912409782014 @default.
• W2091240978 countsByYear W20912409782015 @default.
• W2091240978 countsByYear W20912409782016 @default.
• W2091240978 countsByYear W20912409782017 @default.
• W2091240978 countsByYear W20912409782018 @default.
• W2091240978 countsByYear W20912409782019 @default.
• W2091240978 countsByYear W20912409782021 @default.
• W2091240978 countsByYear W20912409782022 @default.
• W2091240978 countsByYear W20912409782023 @default.
• W2091240978 crossrefType "journal-article" @default.
• W2091240978 hasAuthorship W2091240978A5011410839 @default.
• W2091240978 hasAuthorship W2091240978A5013664294 @default.
• W2091240978 hasAuthorship W2091240978A5015422568 @default.
• W2091240978 hasAuthorship W2091240978A5019669804 @default.
• W2091240978 hasAuthorship W2091240978A5035961207 @default.
• W2091240978 hasAuthorship W2091240978A5089681505 @default.
• W2091240978 hasAuthorship W2091240978A5089784777 @default.
• W2091240978 hasConcept C121608353 @default.
• W2091240978 hasConcept C126322002 @default.
• W2091240978 hasConcept C143998085 @default.
• W2091240978 hasConcept C144301174 @default.
• W2091240978 hasConcept C2777546739 @default.
• W2091240978 hasConcept C2778019345 @default.
• W2091240978 hasConcept C2779013556 @default.
• W2091240978 hasConcept C2780849966 @default.
• W2091240978 hasConcept C2992208098 @default.
• W2091240978 hasConcept C2992571226 @default.
• W2091240978 hasConcept C38180746 @default.
• W2091240978 hasConcept C509974204 @default.
• W2091240978 hasConcept C71924100 @default.
• W2091240978 hasConcept C90924648 @default.
• W2091240978 hasConceptScore W2091240978C121608353 @default.
• W2091240978 hasConceptScore W2091240978C126322002 @default.
• W2091240978 hasConceptScore W2091240978C143998085 @default.
• W2091240978 hasConceptScore W2091240978C144301174 @default.
• W2091240978 hasConceptScore W2091240978C2777546739 @default.
• W2091240978 hasConceptScore W2091240978C2778019345 @default.
• W2091240978 hasConceptScore W2091240978C2779013556 @default.
• W2091240978 hasConceptScore W2091240978C2780849966 @default.
• W2091240978 hasConceptScore W2091240978C2992208098 @default.
• W2091240978 hasConceptScore W2091240978C2992571226 @default.
• W2091240978 hasConceptScore W2091240978C38180746 @default.
• W2091240978 hasConceptScore W2091240978C509974204 @default.
• W2091240978 hasConceptScore W2091240978C71924100 @default.
• W2091240978 hasConceptScore W2091240978C90924648 @default.
• W2091240978 hasIssue "3" @default.
• W2091240978 hasLocation W20912409781 @default.
• W2091240978 hasLocation W20912409782 @default.
• W2091240978 hasOpenAccess W2091240978 @default.
• W2091240978 hasPrimaryLocation W20912409781 @default.
• W2091240978 hasRelatedWork W2141588503 @default.
• W2091240978 hasRelatedWork W2181440008 @default.
• W2091240978 hasRelatedWork W2366034262 @default.
• W2091240978 hasRelatedWork W2388968711 @default.
• W2091240978 hasRelatedWork W2413300445 @default.

• next